Mirena (Levonorgestrel)

Levonorgestrel released from the Mirena device binds to progesterone receptors in the endometrium, causing glandular atrophy and thinning of the uterine lining. It also thickens cervical mucus and suppresses the mid‑cycle luteinizing hormone surge, which together prevent ovulation and create a hostile environment for sperm, resulting in effective contraception and reduced bleeding.

Mirena is supplied as a pre‑loaded intrauterine system that delivers a low, continuous dose of levonorgestrel (approximately 20 µg per day) over several years. The exact dosing regimen, including insertion timing and duration of use, is determined by the prescribing clinician based on the patient’s individual needs.

Mirena must not be inserted in a woman who is already pregnant, and it should be removed if pregnancy occurs. While the device can be removed before conception, it is generally considered safe for women who become pregnant after removal. Limited data exist on use during breastfeeding; clinicians usually advise removal before initiating lactation if possible.

To place an order, submit an enquiry on the Mirena product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Compared with oral contraceptives, Mirena offers a once‑in‑a‑lifetime insertion that provides up to five years of protection without daily adherence. Unlike copper IUDs, it releases a hormone that can reduce menstrual bleeding and associated symptoms. However, it shares some hormonal side‑effects with other progestin‑based methods and requires a clinical procedure for insertion and removal.

Mirena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. The device must be protected from moisture, direct sunlight and extreme temperatures. Healthcare providers should handle the system with clean, sterile technique during insertion to maintain device integrity and prevent contamination.

Mirena is inserted by a qualified healthcare professional into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions. Once placed, the device remains in situ for up to five years, after which it can be removed or replaced by a clinician.

Serious risks include uterine perforation during insertion, device expulsion, pelvic inflammatory disease, and ectopic pregnancy if contraception fails. Women should be educated to seek immediate medical attention for severe abdominal pain, abnormal bleeding, fever, or signs of infection, as these may indicate a complication requiring prompt evaluation.

Mirena is contraindicated in women who are currently pregnant, have known or suspected uterine anomalies, active pelvic infection, untreated cervical or endometrial cancer, or a history of breast cancer that is hormone‑sensitive. It should also be avoided in individuals with unexplained vaginal bleeding or severe liver disease.